Karolinska spin-out in licence with Smiths Medical

Press release from Smiths Medical

Smiths Medical Patient Monitoring and PHASEIN AB announced today that they have signed an agreement in which Smiths Medical receives exclusive USA rights to market PHASEIN's emergency capnometer under the Smiths Medical CAPNOCHECK label. PHASEIN will market the device in other markets under the brand name EMMA. The EMMA/Capnocheck capnometer is the world's first self-contained, real time quantitative capnometer for proof-of-intubation, spot-checking, and short-term CO2 monitoring of adults and children in emergency, transport, and acute care settings. EMMA/ CAPNOCHECK is pending US FDA 510(k) clearance.

“This device equips the first responder and clinical professional with a pocket-sized quantitative capnometer suitable for high acuity settings,” said Ignacio Silva, Smiths Medical Patient Monitoring vice president of sales and marketing. “Capnocheck is a significant breakthrough both clinically and economically in providing instantaneous respiratory data from intubated and non-intubated patients."

“As one of the world's leading gas analysis companies, PHASEIN has an impressive track record in the development and marketing of innovative gas analyzers,” said Robert Zyzanski, CEO of PHASEIN. “We are confident that in Smiths Medical we have found a strong and committed partner for the launch of this novel capnometer in the US market.” ¨

For more information, please contact Smiths Medical PM, Inc., N7W22025 Johnson Drive, Waukesha, WI 53186 USA. 1-800-558-2345, fax 262-542-0718. www.smiths-medical.com.

Smiths Medical PM, Inc. is a designer, manufacturer, and distributor of the BCI® brand of patient monitoring equipment and a distributor of the Pneupac® brand of MRI compatible transport ventilators. Located in Waukesha, Wisconsin, Smiths Medical PM, Inc. is part of Smiths Group, London.

PHASEIN develops, manufactures and markets ultra-small gas monitoring probes, which can be integrated into patient monitors, anesthesia delivery systems, and ventilators. PHASEIN's multi-gas probe IRMA is the size of an oximeter probe and thus overcomes the common shortfalls of traditional monitors. IRMA stands for convenience, mobility and ease of integration. The target groups for the IRMA probes are international medical equipment companies working within the fields of anesthesia, intensive care and emergency care. PHASEIN's in-house tradition and expertise in developing gas analysis systems has resulted in the launch of the world's smallest multi-gas analyzer - the IRMA probe and world's first self-contained, Emergency Capnometer - EMMA. PHASEIN's vision is summarized by the term: PLUG-IN and MEASURE.

Major investors in PHASEIN:
KAROLINSKA INVESTMENT FUND www.karolinskafund.com
SEB FÖRETAGSINVEST www.seb.se/foretagsinvest

For further information contact:
Jeanne Henry at +1 262 542 3100 or [email protected]
Robert Zyzanski at +46 8 544 98 150 or [email protected] / www.phasein.se